Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2– metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study

Background: CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) represent the standard of care for hormone receptor–positive, HER2-negative (HR+/HER2–) metastatic breast cancer (MBC) patients. However, no head-to-head randomized trials have directly compared palbociclib, ribocicli...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Claudia Noto, Lorenzo Foffano, Fabiola Giudici, Elisabetta Molteni, Alessandra Franzoni, Martina Tessitori, Linda Cucciniello, Silvia Bolzonello, Lucia Da Ros, Lucia Bortot, Elena Scudeler, Brenno Pastò, Giulia Cudia, Serena Della Rossa, Marta Bonotto, Alessandro Marco Minisini, Giuseppe Damante, Barbara Belletti, Lorenzo Gerratana, Fabio Puglisi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-04-01
Colecção:	Breast
Assuntos:	Metastatic breast cancer CDK4/6 inhibitors Liquid biopsy Fragmentomics Methylomics Circulating tumor DNA
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S0960977626000135
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!